Literature DB >> 30773743

Is gastroparesis a gastric disease?

Rosanna F Cogliandro1, Giada Rizzoli1, Lara Bellacosa1, Roberto De Giorgio2, Cesare Cremon1, Giovanni Barbara1, Vincenzo Stanghellini1.   

Abstract

BACKGROUND: Gastroparesis is a digestive syndrome characterized by delayed gastric emptying (GE) and by symptoms that are suggestive of gastroduodenal motor disorders. There are three grades of gastroparesis of increasing severity: (a) mild gastroparesis; (b) compensated gastroparesis; and (c) gastric failure. GE abnormalities are partially related to symptom type and severity, and other mechanisms may be involved. AIM: To investigate enteric dysmotility (ED) in patients with suspected gastroparesis.
METHODS: Patients with symptoms suggestive of gastroparesis were consecutively included in the study and underwent a 13 C-octanoic acid GE breath test and small bowel manometry (SBM). Clinical features were recorded using predefined, validated questionnaires at entry. KEY
RESULTS: The study enrolled 88 patients (71 women; mean age: 37.8 ± 14.3 years). Gastric emptying was delayed in 25 patients (28.4%), and 70 patients (79.5%) presented small bowel motor abnormalities including bursts, abnormal activity fronts, inability to respond to meal ingestion, and hypocontractility. Gastric emptying was delayed in 24 of the 70 patients with ED (34.3% vs 5.5% of patients with normal SBM). Enteric dysmotility was detected in 24 of 25 patients (96%) with delayed GE. Patients with and without delayed GE showed similar moderate/severe gastroparesis manifestations, but patients with ED significantly more often had moderate/severe gastroparesis manifestations than patients with normal SBM (grade 1:14% vs 39%, grade 2:62% vs 56%, grade 3:24% vs 5%, respectively). CONCLUSIONS AND INFERENCES: Enteric dysmotility was more frequent than delayed GE in patients with symptoms suggestive of gastroparesis. Gastroparesis severity was associated with small bowel motor abnormalities but not with delayed GE.
© 2019 John Wiley & Sons Ltd.

Entities:  

Keywords:  gastric emptying; gastrointestinal symptoms; gastroparesis; manometry; small bowel motility

Mesh:

Year:  2019        PMID: 30773743     DOI: 10.1111/nmo.13562

Source DB:  PubMed          Journal:  Neurogastroenterol Motil        ISSN: 1350-1925            Impact factor:   3.598


  6 in total

Review 1.  Gastroparesis: a turning point in understanding and treatment.

Authors:  Madhusudan Grover; Gianrico Farrugia; Vincenzo Stanghellini
Journal:  Gut       Date:  2019-09-28       Impact factor: 23.059

2.  Liraglutide accelerates colonic transit in people with type 1 diabetes and polyneuropathy: A randomised, double-blind, placebo-controlled trial.

Authors:  Anne-Marie Langmach Wegeberg; Christian Stevns Hansen; Adam D Farmer; Jesper Scott Karmisholt; Asbjorn M Drewes; Poul Erik Jakobsen; Birgitte Brock; Christina Brock
Journal:  United European Gastroenterol J       Date:  2020-05-09       Impact factor: 4.623

3.  Comment on Suresh et al. The Short-Term Effects and Tolerability of Low-Viscosity Soluble Fibre on Gastroparesis Patients: A Pilot Clinical Intervention Study. Nutrients 2021, 13, 4298.

Authors:  J Wesley Jones; Katrina Lamont; Grace D Brannan
Journal:  Nutrients       Date:  2022-04-28       Impact factor: 6.706

4.  Gastroparesis Symptoms Associated with Intestinal Hypomotility: An Explorative Study Using Wireless Motility Capsule.

Authors:  Mattis Bekkelund; Dag A Sangnes; Eirik Søfteland; Lars Aabakken; Martin Biermann; Elisabeth K Steinsvik; Trygve Hausken; Georg Dimcevski; Jan Gunnar Hatlebakk
Journal:  Clin Exp Gastroenterol       Date:  2021-04-28

Review 5.  Gastroparesis: A Multidisciplinary Approach to Management.

Authors:  Stella-Maris Chinma Egboh; Sarah Abere
Journal:  Cureus       Date:  2022-01-16

6.  The Effect of Continuous Intake of Lactobacillus gasseri OLL2716 on Mild to Moderate Delayed Gastric Emptying: A Randomized Controlled Study.

Authors:  Toshihiro Ohtsu; Ken Haruma; Yumiko Ide; Atsushi Takagi
Journal:  Nutrients       Date:  2021-05-28       Impact factor: 5.717

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.